The NK Cell-cancer Cycle: Advances and New Challenges in NK Cell-based Immunotherapies

Overview

Journal Nat Immunol

Date 2020 Jul 22

PMID 32690952

Citations 217

Authors

Tobias Bald

Matthew F Krummel

Mark J Smyth

Kevin C Barry

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cells belong to the innate immune system and contribute to protecting the host through killing of infected, foreign, stressed or transformed cells. Additionally, via cellular cross-talk, NK cells orchestrate antitumor immune responses. Hence, significant efforts have been undertaken to exploit the therapeutic properties of NK cells in cancer. Current strategies in preclinical and clinical development include adoptive transfer therapies, direct stimulation, recruitment of NK cells into the tumor microenvironment (TME), blockade of inhibitory receptors that limit NK cell functions, and therapeutic modulation of the TME to enhance antitumor NK cell function. In this Review, we introduce the NK cell-cancer cycle to highlight recent advances in NK cell biology and to discuss the progress and problems of NK cell-based cancer immunotherapies.

Citing Articles

Overexpression of NKG2D and IL24 in NK Cell-Derived Exosomes for Cancer Therapy.

Huang C, Hu Q, Wang P, Xie M, Zhang Y, Li Z Int J Mol Sci. 2025; 26(5).

PMID: 40076725 PMC: 11901126. DOI: 10.3390/ijms26052098.

Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L Bioeng Transl Med. 2025; 10(2):e10716.

PMID: 40060757 PMC: 11883117. DOI: 10.1002/btm2.10716.

GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint.

Hui X, Xue M, Ren Y, Chen Y, Chen X, Farooq M Sci Adv. 2025; 11(10):eadr9395.

PMID: 40043109 PMC: 11881902. DOI: 10.1126/sciadv.adr9395.

In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma.

Courot H, Rigal E, Adib N, Criton M, Cookson A, Fauvel B Cells. 2025; 14(4).

PMID: 39996727 PMC: 11854314. DOI: 10.3390/cells14040254.

Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.

Zhang Z, Zhao J, Li Y, Zhang H, Chen Y, Yang L Discov Oncol. 2025; 16(1):205.

PMID: 39969618 PMC: 11839965. DOI: 10.1007/s12672-025-01963-z.

References

Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo J, Eberl G . Innate Lymphoid Cells: 10 Years On. Cell. 2018; 174(5):1054-1066. DOI: 10.1016/j.cell.2018.07.017. View

Colonna M . Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity. Immunity. 2018; 48(6):1104-1117. PMC: 6344351. DOI: 10.1016/j.immuni.2018.05.013. View

Chiossone L, Dumas P, Vienne M, Vivier E . Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018; 18(11):671-688. DOI: 10.1038/s41577-018-0061-z. View

Lopez-Soto A, Gonzalez S, Smyth M, Galluzzi L . Control of Metastasis by NK Cells. Cancer Cell. 2017; 32(2):135-154. DOI: 10.1016/j.ccell.2017.06.009. View

Gasteiger G, Rudensky A . Interactions between innate and adaptive lymphocytes. Nat Rev Immunol. 2014; 14(9):631-9. PMC: 4504695. DOI: 10.1038/nri3726. View

Crinier A, Milpied P, Escaliere B, Piperoglou C, Galluso J, Balsamo A . High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. Immunity. 2018; 49(5):971-986.e5. PMC: 6269138. DOI: 10.1016/j.immuni.2018.09.009. View

Collins P, Cella M, Porter S, Li S, Gurewitz G, Hong H . Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells. Cell. 2019; 176(1-2):348-360.e12. PMC: 6329660. DOI: 10.1016/j.cell.2018.11.045. View

Frey M, Packianathan N, Fehniger T, Ross M, Wang W, Stewart C . Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol. 1998; 161(1):400-8. View

Sedlmayr P, Schallhammer L, Hammer A, Wilders-Truschnig M, Wintersteiger R, Dohr G . Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. Int Arch Allergy Immunol. 1996; 110(4):308-13. DOI: 10.1159/000237321. View

10.

Hayakawa Y, Huntington N, Nutt S, Smyth M . Functional subsets of mouse natural killer cells. Immunol Rev. 2006; 214:47-55. DOI: 10.1111/j.1600-065X.2006.00454.x. View

11.

Hayakawa Y, Smyth M . CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006; 176(3):1517-24. DOI: 10.4049/jimmunol.176.3.1517. View

12.

Peng H, Tian Z . Diversity of tissue-resident NK cells. Semin Immunol. 2017; 31:3-10. DOI: 10.1016/j.smim.2017.07.006. View

13.

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

14.

Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V . CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol. 2014; 192(8):3805-15. DOI: 10.4049/jimmunol.1301889. View

15.

Wu M, Mei F, Liu W, Jiang J . Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. Biomed Pharmacother. 2019; 121:109637. DOI: 10.1016/j.biopha.2019.109637. View

16.

Nath P, Pal-Nath D, Mandal A, Cam M, Schwartz A, Roberts D . Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment. Cancer Immunol Res. 2019; 7(9):1547-1561. PMC: 6726576. DOI: 10.1158/2326-6066.CIR-18-0367. View

17.

Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S . A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients. Cancer Immunol Res. 2019; 7(7):1162-1174. DOI: 10.1158/2326-6066.CIR-18-0500. View

18.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

19.

Bottcher J, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S . NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018; 172(5):1022-1037.e14. PMC: 5847168. DOI: 10.1016/j.cell.2018.01.004. View

20.

Ali T, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C . Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014; 5:5639. PMC: 4338526. DOI: 10.1038/ncomms6639. View